The supernova impostor SN 2010da located in the nearby galaxy NGC 300, later identified as a likely supergiant B[e] high-mass X-ray binary, was simultaneously observed by NuSTAR and XMM-Newton between 2016 December 16 and 20, over a total time span of ∼310 ks. We report the discovery of a strong periodic modulation in the X-ray flux with a pulse period of 31.6 s and a very rapid spin-up, and confirm therefore that the compact object is a neutron star. We find that the spin period is changing from 31.71 s to 31.54 s over that period, with a spin-up rate of −5.56 × 10 −7 s s −1 , likely the largest ever observed from an accreting neutron star. The spectrum is described by a power-law and a disk black-body model, leading to a 0.3-30 keV unabsorbed luminosity of 4.7 × 10 39 erg s −1 . Applying our best-fit model successfully to the spectra of an XMM-Newton observation from 2010, suggests that the lower fluxes of NGC 300 ULX1 reported from observations around that time are caused by a large amount of absorption, while the intrinsic luminosity was similar as seen in 2016. A more constant luminosity level is also consistent with the long-term pulse period evolution approaching an equilibrium value asymptotically. We conclude that the source is another candidate for the new class of ultraluminous X-ray pulsars.

Aims. We present a comprehensive X-ray study of the population of supernova remnants (SNRs) in the Large Magellanic Cloud (LMC). Using primarily XMM-Newton observations, we conduct a systematic spectral analysis of LMC SNRs to gain new insight into their evolution and the interplay with their host galaxy. Methods. We combined all the archival XMM-Newton observations of the LMC with those of our Very Large Programme LMC survey. We produced X-ray images and spectra of 51 SNRs, out of a list of 59 objects compiled from the literature and augmented with newly found objects. Using a careful modelling of the background, we consistently analysed all the X-ray spectra and measure temperatures, luminosities, and chemical compositions. The locations of SNRs are compared to the distributions of stars, cold gas, and warm gas in the LMC, and we investigated the connection between the SNRs and their local environment, characterised by various star formation histories. We tentatively typed all LMC SNRs, in order to constrain the ratio of core-collapse to type Ia SN rates in the LMC. We also compared the column densities derived from X-ray spectra to H i maps, thus probing the three-dimensional structure of the LMC. Results. This work provides the first homogeneous catalogue of the X-ray spectral properties of SNRs in the LMC. It offers a complete census of LMC remnants whose X-ray emission exhibits Fe K lines (13% of the sample), or reveals the contribution from hot supernova ejecta (39%), which both give clues to the progenitor types. The abundances of O, Ne, Mg, Si, and Fe in the hot phase of the LMC interstellar medium are found to be between 0.2 and 0.5 times the solar values with a lower abundance ratio [α/Fe] than in the Milky Way. The current ratio of core-collapse to type Ia SN rates in the LMC is constrained to N CC /N Ia = 1.35( +0.11 −0.24 ), which is lower than in local SN surveys and galaxy clusters. Our comparison of the X-ray luminosity functions of SNRs in Local Group galaxies (LMC, SMC, M31, and M33) reveals an intriguing excess of bright objects in the LMC. Finally, we confirm that 30 Doradus and the LMC Bar are offset from the main disc of the LMC to the far and near sides, respectively.

Aims. In light of recent discoveries of pulsating ultraluminous X-ray sources (ULXs) and recently introduced theoretical schemes that propose neutron stars (NSs) as the central engines of ULXs, we revisit the spectra of eighteen well known ULXs, in search of indications that favour this newly emerging hypothesis. Methods. We examine the spectra from high-quality XMM-Newton and NuSTAR observations. We use a combination of elementary black body and multicolour disk black body (MCD) models, to diagnose the predictions of classic and novel theoretical models of accretion onto NSs. We re-interpret the well established spectral characteristics of ULXs in terms of accretion onto lowly or highly magnetised NSs, and explore the resulting parameter space for consistency. Results. We confirm the previously noted presence of the low-energy ( 6 keV) spectral rollover and argue that it could be interpreted as due to thermal emission. The spectra are well described by a double thermal model consisting of a "hot" ( 1 keV) and a "cool" ( 0.7 keV) multicolour black body (MCB). Under the assumption that the "cool" MCD emission originates in a disk truncated at the neutron star magnetosphere, we find that all ULXs in our sample are consistent with accretion onto a highly magnetised (B 10 12 G) neutron star. We note a strong correlation between the strength of the magnetic field, the temperature of the "hot" thermal component and the total unabsorbed luminosity. Examination of the NuSTAR data supports this interpretation and also confirms the presence of a weak, high-energy ( 15 keV) tail, most likely the result of modification of the MCB emission by inverse Compton scattering. We also note that the apparent high-energy tail, may simply be the result of mismodelling of MCB emission with an atypical temperature (T ) versus radius (r) gradient, using a standard MCD model with a fixed gradient of T ∼r −0.75 . Conclusions. We have offered a new and robust physical interpretation for the dual-thermal spectra of ULXs. We find that the best-fit derived parameters of our model, are in excellent agreement with recent theoretical predictions that favour super-critically accreting NSs as the engines of a large fraction of ULXs. Nevertheless, the considerable degeneracy between models and the lack of unequivocal evidence cannot rule out other equally plausible interpretations. Deeper broadband observations and time-resolved spectroscopy are warranted to further explore this newly emerging framework.

In the current work we explore the applicability of standard theoretical models of accretion to the observed properties of M51 ULX-7. The spin-up rate and observed X-ray luminosity are evidence of a neutron star with a surface magnetic field of 2 − 7 × 10 13 G, rotating near equilibrium. Analysis of the X-ray light-curve of the system (Swift/XRT data) reveals the presence of a ∼39 d super-orbital period. We argue that the super-orbital periodicity is due to disc precession, and that material is accreted onto the neutron star at a constant rate throughout it. Moreover, by attributing this modulation to the free precession of the neutron star we estimate a surface magnetic field strength of 3 − 4 × 10 13 G. The agreement of these two independent estimates provide strong constraints on the surface polar magnetic field strength of the neutron star.

See Appendix for individual names.Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. Patients and methods:In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (q3w)] and pertuzumab (840 mg loading dose, then 420 mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). Results:Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nabpaclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%).Conclusions: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile.ClinicalTrials.gov: NCT01572038.